Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept Switch for CNI Toxicity in Kidney Transplant
NCT01953120Phase 4Completed
- Sponsor
- University of California, Los Angeles
- Start
- Oct 2013
- Primary completion
- Apr 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of belatacept in kidney transplant rejection, sponsored by University of California, Los Angeles. Primary endpoint: Antibody and T Cell-mediated Immune Response at 6 months. Started Oct 2013; status: completed.
02
Drugs
belatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT01953120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01953120.